Baotou Dongbao Bio-Tech Co.,Ltd (SHE:300239)
6.28
+0.03 (0.48%)
Feb 4, 2026, 3:04 PM CST
SHE:300239 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 749.89 | 850.21 | 970.41 | 937.89 | 609.82 | 446.33 |
Other Revenue | 34.72 | 34.72 | 4.1 | 5.51 | 2.34 | 2.5 |
| 784.62 | 884.93 | 974.51 | 943.4 | 612.17 | 448.83 | |
Revenue Growth (YoY) | -10.12% | -9.19% | 3.30% | 54.11% | 36.39% | -8.79% |
Cost of Revenue | 600.13 | 687.88 | 728.53 | 712.28 | 515.98 | 381.95 |
Gross Profit | 184.49 | 197.06 | 245.98 | 231.12 | 96.19 | 66.87 |
Selling, General & Admin | 71.37 | 67.96 | 69.75 | 67.81 | 40.1 | 32.91 |
Research & Development | 30.26 | 27.36 | 26.1 | 25.83 | 12.98 | 9.94 |
Other Operating Expenses | 6.09 | 4.92 | 12.58 | 12.52 | 9.23 | 5.71 |
Operating Expenses | 107.48 | 99.82 | 110.21 | 106.47 | 62.34 | 47.49 |
Operating Income | 77.01 | 97.23 | 135.77 | 124.65 | 33.85 | 19.38 |
Interest Expense | -3.76 | -2.56 | -5.14 | -7.63 | -4.78 | -5.87 |
Interest & Investment Income | 3.58 | 7.11 | 6.37 | 4.84 | 2.88 | 0.52 |
Currency Exchange Gain (Loss) | 1.03 | 1.03 | 0.26 | 0.7 | -0.03 | -0.07 |
Other Non Operating Income (Expenses) | 0.48 | -0.18 | -0.17 | -0.21 | 1.44 | -0.84 |
EBT Excluding Unusual Items | 78.34 | 102.63 | 137.08 | 122.35 | 33.37 | 13.12 |
Gain (Loss) on Sale of Investments | -2.9 | -3.74 | -4.33 | -1.91 | -2.53 | -1.4 |
Gain (Loss) on Sale of Assets | -0.08 | -0.28 | 0.08 | 0.14 | 0.09 | 0.01 |
Asset Writedown | -4.08 | -0.88 | -0.86 | -0.42 | -0.6 | -0.11 |
Other Unusual Items | 8.31 | 7.79 | 12.47 | 11.25 | 11.21 | 8.04 |
Pretax Income | 79.71 | 105.63 | 144.49 | 131.65 | 41.54 | 19.66 |
Income Tax Expense | 11.53 | 14.37 | 17.12 | 16.21 | 5.72 | 1.47 |
Earnings From Continuing Operations | 68.18 | 91.26 | 127.37 | 115.44 | 35.82 | 18.19 |
Minority Interest in Earnings | -0.02 | -5.28 | -7.49 | -6 | 0.66 | 0.26 |
Net Income | 68.16 | 85.98 | 119.89 | 109.44 | 36.48 | 18.45 |
Net Income to Common | 68.16 | 85.98 | 119.89 | 109.44 | 36.48 | 18.45 |
Net Income Growth | -25.02% | -28.28% | 9.55% | 199.96% | 97.74% | -43.95% |
Shares Outstanding (Basic) | 588 | 594 | 593 | 593 | 564 | 523 |
Shares Outstanding (Diluted) | 637 | 647 | 612 | 593 | 564 | 523 |
Shares Change (YoY) | -2.31% | 5.72% | 3.12% | 5.25% | 7.89% | 3.06% |
EPS (Basic) | 0.12 | 0.14 | 0.20 | 0.18 | 0.06 | 0.04 |
EPS (Diluted) | 0.11 | 0.13 | 0.20 | 0.18 | 0.06 | 0.04 |
EPS Growth | -23.25% | -32.16% | 6.24% | 185.01% | 83.29% | -45.61% |
Free Cash Flow | 36.65 | -8.04 | 67.15 | 86.76 | 0.15 | -88.8 |
Free Cash Flow Per Share | 0.06 | -0.01 | 0.11 | 0.15 | - | -0.17 |
Dividend Per Share | 0.025 | 0.025 | 0.022 | 0.026 | 0.006 | - |
Dividend Growth | 13.64% | 13.64% | -15.38% | 333.33% | - | - |
Gross Margin | 23.51% | 22.27% | 25.24% | 24.50% | 15.71% | 14.90% |
Operating Margin | 9.81% | 10.99% | 13.93% | 13.21% | 5.53% | 4.32% |
Profit Margin | 8.69% | 9.72% | 12.30% | 11.60% | 5.96% | 4.11% |
Free Cash Flow Margin | 4.67% | -0.91% | 6.89% | 9.20% | 0.02% | -19.79% |
EBITDA | 166.61 | 183.56 | 217.73 | 210.16 | 89.17 | 68.08 |
EBITDA Margin | 21.23% | 20.74% | 22.34% | 22.28% | 14.57% | 15.17% |
D&A For EBITDA | 89.59 | 86.32 | 81.96 | 85.52 | 55.32 | 48.69 |
EBIT | 77.01 | 97.23 | 135.77 | 124.65 | 33.85 | 19.38 |
EBIT Margin | 9.81% | 10.99% | 13.93% | 13.21% | 5.53% | 4.32% |
Effective Tax Rate | 14.46% | 13.60% | 11.85% | 12.31% | 13.76% | 7.47% |
Revenue as Reported | 784.62 | 884.93 | 974.51 | 943.4 | 612.17 | 448.83 |
Advertising Expenses | - | 0.57 | 1.12 | 1.08 | 0.81 | 1.65 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.